We are live on
!
Find out more
PAP
Persistent Asset Partners Portfolio holdings
AUM
$335M
1-Year Est. Return
275.57%
This Fund
S&P 500
This Quarter
Est. Return
+39.3%
1 Year Est. Return
+275.57%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$223M
AUM Growth
+$77.2M
(+53%)
Cap. Flow
+$50.2M
Cap. Flow
% of AUM
22.55%
Top 10 Holdings %
Top 10 Hldgs %
25.3%
Holding
464
New
223
Increased
67
Reduced
60
Closed
103
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Molina Healthcare
MOH
|
+$8.43M |
| 2 |
Elevance Health
ELV
|
+$5.15M |
| 3 |
Intel
INTC
|
+$4.26M |
| 4 |
SNDK
Sandisk
SNDK
|
+$3.61M |
| 5 |
Johnson & Johnson
JNJ
|
+$3.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 7-10 Year Treasury Bond ETF
IEF
|
+$4.82M |
| 2 |
UnitedHealth
UNH
|
+$3.15M |
| 3 |
iShares Bitcoin Trust
IBIT
|
+$2.87M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$2.84M |
| 5 |
Labcorp
LH
|
+$2.58M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 52.36% |
| 2 | Technology | 13.57% |
| 3 | Financials | 11.27% |
| 4 | Miscellaneous | 7.53% |
| 5 | Communication Services | 4.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
Karyopharm Therapeutics
KPTI
$40.6M
| $135K | 0.06% |
+18,316
| New | +$112K |
|
252
Nike
NKE
$57B
| $134K | 0.06% |
2,100
-225
| -10% | -$14.7K |
|
253
Coherent
COHR
$55.2B
| $129K | 0.06% |
+700
| New | +$105K |
|
254
Travere Therapeutics
TVTX
$6.15B
| $126K | 0.06% |
+3,291
| New | +$107K |
|
255
Broadcom
AVGO
$1.7T
| $125K | 0.06% |
+360
| New | +$129K |
|
256
Bloom Energy
BE
$74.5B
| $121K | 0.05% |
1,397
-2,789
| -67% | -$293K |
|
257
PUT
Intellia Therapeutics
NTLA
$1.79B
| $118K | 0.05% |
+852
| New | +$11.7K |
|
|
AVR
258
Anteris Technologies
AVR
$881M
| $116K | 0.05% |
23,317
| – | – |
|
|
DBVT
259
DBV Technologies
DBVT
$847M
| $115K | 0.05% |
+6,019
| New | +$94K |
|
260
Certara
CERT
$1.21B
| $113K | 0.05% |
+12,791
| New | +$132K |
|
261
MoonLake Immunotherapeutics
MLTX
$1.28B
| $112K | 0.05% |
+8,523
| New | +$101K |
|
262
Adaptive Biotechnologies
ADPT
$3.87B
| $109K | 0.05% |
+6,689
| New | +$109K |
|
|
BLTE
263
Belite Bio
BLTE
$7.8B
| $108K | 0.05% |
+673
| New | +$79.7K |
|
|
BBOT
264
BridgeBio Oncology
BBOT
$720M
| $107K | 0.05% |
+8,585
| New | +$104K |
|
265
First Solar
FSLR
$22B
| $103K | 0.05% |
393
-307
| -44% | -$77.4K |
|
266
Surrozen
SRZN
$268M
| $98.5K | 0.04% |
+4,359
| New | +$70.5K |
|
267
EyePoint Inc
EYPT
$395M
| $98.4K | 0.04% |
+5,387
| New | +$76.3K |
|
268
Dentsply Sirona
XRAY
$2.27B
| $98.4K | 0.04% |
+8,605
| New | +$101K |
|
269
International Seaways
INSW
$5.18B
| $97.1K | 0.04% |
+2,000
| New | +$98.9K |
|
270
Castle Biosciences
CSTL
$1.01B
| $95.8K | 0.04% |
+2,463
| New | +$79.4K |
|
271
Enova International
ENVA
$5.74B
| $95.6K | 0.04% |
+608
| New | +$79.1K |
|
272
Denali Therapeutics
DNLI
$3.56B
| $93.6K | 0.04% |
+5,670
| New | +$95.7K |
|
273
Envista
NVST
$4.38B
| $92.6K | 0.04% |
+4,264
| New | +$87.5K |
|
274
ProQR Therapeutics
PRQR
$292M
| $91.2K | 0.04% |
45,154
+8,874
| +24% | +$20.7K |
|
|
LBRX
275
LB Pharmaceuticals
LBRX
$1.59B
| $90.8K | 0.04% |
+4,080
| New | +$71.3K |
|
Similar funds
JWM
PI
TFA
SIM
OWM
SS
BIA
ATC
Persistent Asset Partners's Q4 2025 Portfolio in Review
As of Q4 2025, Persistent Asset Partners held 464 positions worth $223M, up 53% from $145M the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Persistent Asset Partners deployed $50.2M of net new capital in Q4 2025, opening 223 new positions and adding to 67 existing holdings. Its largest new stake was Molina Healthcare: 51,285 shares worth $8.9M.
By sector, the portfolio is most concentrated in Healthcare at 52% of assets, up from 49% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was UnitedHealth, an estimated $3.15M trimmed.
- Persistent Asset Partners's largest Q4 2025 buy was Molina Healthcare: 51,285 shares worth $8.9M.
- Persistent Asset Partners added most to Elevance Health in Q4 2025, an estimated $5.15M increase.
- Persistent Asset Partners's biggest Q4 2025 reduction was UnitedHealth, cutting an estimated $3.15M.
- Persistent Asset Partners fully exited iShares 7-10 Year Treasury Bond ETF in Q4 2025, selling an estimated $4.82M.
- Persistent Asset Partners's ten largest holdings make up 25% of its $223M portfolio in Q4 2025.
- Persistent Asset Partners opened 223 new positions and closed 103 in Q4 2025.
- Persistent Asset Partners's portfolio value rose 53% quarter-over-quarter to $223M.
Based on Persistent Asset Partners's 13F filing for Q4 2025, filed 17 Feb 2026.